SOPHiA GENETICS presents New Generation SOPHiA DDM Platform at XXXVII CBGM, São Luís, Maranhão; Exome advancements for precision medicine.

SOPHiA GENETICS presents New Generation SOPHiA DDM Platform at XXXVII CBGM, São Luís, Maranhão; Exome advancements for precision medicine.

XXXVII Congresso Brasileiro de Genética Médica e Genômica - SOPHiA GENETICS

XXXVII Congresso Brasileiro de Genética Médica e Genômica

Hereditary Disorders , SOPHiA DDM™ Platform

Home XXXVII Congresso Brasileiro de Genética Médica e Genômica

SOPHiA GENETICS is proud to join the 37th CBGM in São Luís, Maranhão (Sept 2–5, 2026), celebrating 40 years of SBGM and the future of precision medicine in Brazil. Meet us at Booth #20 to discover the latest innovations of the New Generation SOPHiA DDM™ Platform, with a special focus on Exome advancements.

This field is hidden when viewing the form

The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.

The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.

SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at

to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and

or services and shall be considered nominative fair use under the trademark law.